Zoetis and Idexx are the two leading pure-play companies in the animal health industry. As discussed in my previous article just here, this sector is particularly appealing due to its high margins, lower risk profile (including fewer legal and regulatory hurdles and smoother patent expiration impacts).
Both companies excel in key areas such as margin performance, growth potential, return on invested capital (ROIC), and management quality. However, they exhibit some notable differences: Idexx tends to be more dynamic and carries less debt, while Zoetis is larger, more diversified, and offers a more attractive valuation.
In the comparison, Zoetis emerges as the preferred choice. Although growth prospects are comparable between the two, Zoetis benefits from a better valuation and a larger scale, which provide it with a competitive advantage. However, both appear to be good investment choice.
If you like stock duels, you can find here the previous ones:
Any specific reason why zoetis has been stagnating?